drugset
drugset / Trial / NCT00395018

Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection

NCT00395018 ↗

Phase 3 Completed 109 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this clinical research study is to learn if the study drug entecavir will prevent the recurrence of hepatitis B virus (HBV) in participants who receive an orthotopic liver transplant (OLT) due to HBV infection.

Timeline

Start
2007-04
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Entecavir Small molecule 1 mg Oral

Indications

chronic hepatitis B virus infection